Provided is the use of a therapeutically effective amount of placental stem cells in the manufacture of a composition for use in treating an individual having a disease, disorder or condition of the lung, wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in one or more symptoms of said disease, disorder or condition； and wherein said disease, disorder or condition of the lung is interstitial pulmonary fibrosis, pulmonary sarcoidosis, asthma, bronchitis, acute respiratory distress syndrome, or chronic obstructive pulmonary disease.
